GO:1902214 regulation of interleukin-4-mediated signaling pathway: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902214 describes any process that modulates the frequency, rate or extent of the interleukin-4-mediated signaling pathway [1, 5].
• The pathway is primarily regulated through post-translational modifications of STAT6, including phosphorylation and dephosphorylation [1, 3].
• Negative regulators such as dominant-negative STAT6 and protein phosphatase 2A attenuate IL-4 signaling [1, 3].
• Positive regulators such as SHIP and Bcl-xL enhance IL-4-mediated proliferation and survival [2, 4].
• Dysregulation of this pathway is implicated in cancer, infection, and immune disorders [6, 7, 8].
• CRISPR-based models enable precise interrogation of regulatory nodes in IL-4 signaling [1, 2, 3, 4, 5, 6, 7, 8].
Description
The Gene Ontology term GO:1902214, regulation of interleukin-4-mediated signaling pathway, encompasses any process that modulates the frequency, rate or extent of the signaling cascade initiated by the cytokine interleukin-4 (IL-4) [1, 5]. IL-4 is a pleiotropic cytokine that drives Th2 differentiation, B-cell survival, and alternative macrophage activation, and its signaling is tightly controlled to prevent pathological outcomes. The pathway is primarily transduced through the IL-4 receptor and the Janus kinase (JAK)-signal transducer and activator of transcription 6 (STAT6) axis, which is subject to multiple layers of regulation [1, 3]. Regulation of IL-4-mediated signaling is critical for immune homeostasis, and its perturbation contributes to diseases ranging from cancer to chronic infections [6, 7, 8]. For researchers, understanding the molecular players that fine-tune this pathway is essential for developing targeted therapies and for interpreting experimental models of immune function [2, 4]. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:1902214, its mechanisms, key genes, and methods for study.
regulation of interleukin-4-mediated signaling pathway At A Glance
| GO ID | GO:1902214 |
|---|---|
| GO term | regulation of interleukin-4-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of IL-4-mediated signaling pathway; regulation of interleukin-4-mediated signalling pathway |
| Major function | Modulates the frequency, rate or extent of IL-4-mediated signaling |
| Key regulators | STAT6, PP2A, SHIP, Bcl-xL, SOCS proteins |
| Associated diseases | Cancer, gastric metaplasia, viral latency, immune dysregulation |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:1902214?
GO:1902214 is defined as any biological process that modulates the frequency, rate or extent of the interleukin-4-mediated signaling pathway. In other words, it includes all molecular events that positively or negatively adjust the strength, duration, or outcome of IL-4 signal transduction, such as alterations in receptor availability, kinase/phosphatase activity, or downstream transcription factor function [1, 3, 5].
Why Is regulation of interleukin-4-mediated signaling pathway Important in Cell Biology?
Regulation of IL-4-mediated signaling is essential for balancing protective immunity and preventing pathological inflammation or tumorigenesis. Dysregulation of this pathway is linked to cancer progression, chronic infections, and autoimmune conditions, making its components attractive therapeutic targets and biomarkers [6, 7, 8]. Understanding the regulatory mechanisms provides insight into how cells interpret cytokine signals and offers opportunities for precision medicine [1, 2, 3, 4, 5].
• Controls B-cell survival and apoptosis through Stat6-dependent upregulation of Bcl-xL.
• Modulates allergic inflammation and Th2 immune responses.
• Influences tumor microenvironment and resistance to chemotherapy.
• Regulates gastric mucosal intestinal metaplasia induced by Helicobacter pylori.
• Affects viral latency and apoptosis in Kaposi's sarcoma-associated herpesvirus infection.
• Provides targets for anti-inflammatory and anti-cancer therapies [1, 3].
• Serves as a paradigm for cytokine signaling regulation [2, 5].
• Enables mechanistic studies using CRISPR-edited cell models [1, 2, 3, 4, 5, 6, 7, 8].
What Happens During regulation of interleukin-4-mediated signaling pathway?
Receptor engagement and JAK activation
In simple terms: IL-4 binds to its receptor, which activates JAK kinases to start the signal.
IL-4 binds to the IL-4 receptor, triggering JAK-mediated phosphorylation of the receptor and recruitment of STAT6 [1, 5]. This initial step is subject to regulation by receptor availability and negative feedback loops.
STAT6 phosphorylation and dimerization
In simple terms: STAT6 gets tagged with phosphate groups, pairs up, and moves to the nucleus.
Phosphorylated STAT6 forms dimers that translocate to the nucleus to activate transcription of IL-4-responsive genes [1, 5]. Naturally occurring dominant-negative STAT6 variants can block this step, attenuating signaling.
Dephosphorylation by phosphatases
In simple terms: Enzymes called phosphatases remove phosphate tags to turn off the signal.
Protein phosphatase 2A (PP2A) dephosphorylates STAT6, thereby terminating IL-4-mediated STAT6 signaling. This represents a key negative regulatory mechanism.
Positive regulation by SHIP and Bcl-xL
In simple terms: Other proteins can boost the signal to promote cell growth and survival.
The SH2-containing inositol-5'-phosphatase (SHIP) positively regulates IL-4-mediated proliferation. Additionally, Stat6-dependent upregulation of Bcl-xL protects primary B cells from apoptosis.
Pathogen-mediated modulation
In simple terms: Some pathogens interfere with the IL-4 signal to survive.
Helicobacter pylori inhibits IL-4-mediated Sox2 expression to induce gastric metaplasia, while Kaposi's sarcoma-associated herpesvirus inhibits STAT6 phosphorylation to maintain latency.
Key Genes Involved in GO:1902214 regulation of interleukin-4-mediated signaling pathway
The following genes and proteins are central to the regulation of IL-4-mediated signaling, as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STAT6 | Transcription factor mediating IL-4 responses | Dominant-negative forms attenuate signaling |
| PP2A | Phosphatase that dephosphorylates STAT6 | Negative regulator of IL-4 signaling |
| SHIP | Inositol phosphatase positively regulating proliferation | Enhances IL-4-mediated proliferation |
| Bcl-xL | Anti-apoptotic protein upregulated by Stat6 | Protects B cells from apoptosis |
| SOCS | Suppressors of cytokine signaling | Feedback inhibition of IL-4 pathway |
| JAK1 | Janus kinase activated by IL-4 receptor | Initiates STAT6 phosphorylation |
| JAK3 | Janus kinase associated with IL-4 receptor | Initiates STAT6 phosphorylation |
| IL4R | IL-4 receptor alpha chain | Binds IL-4 and initiates signaling |
| Sox2 | Transcription factor inhibited by IL-4 | Involved in gastric metaplasia |
| KSHV ORF | Viral proteins inhibiting STAT6 | Regulate apoptosis and latency |
| Bax | Pro-apoptotic protein regulated by microenvironment | Modulated by Bcl-X(L) |
| HMG box protein | Sox2-related factor | Inhibited by IL-4 in metaplasia |
| STAT6 variants | Naturally occurring dominant-negative forms | Attenuate IL-4 signaling |
| PP2A subunits | Catalytic and regulatory subunits | Regulate STAT6 phosphorylation |
| SHIP1 | SH2-containing inositol-5'-phosphatase | Positive regulator of IL-4 proliferation |
| Bcl-X(L) | Anti-apoptotic isoform | Upregulated by Stat6 |
| SOCS1 | Cytokine signaling suppressor | Negative feedback |
How Is regulation of interleukin-4-mediated signaling pathway Regulated?
The regulation of IL-4-mediated signaling is achieved through multiple mechanisms, including phosphatase-mediated dephosphorylation of STAT6 by PP2A, dominant-negative STAT6 variants, and positive regulation by SHIP. Additionally, pathogen-derived factors can modulate the pathway, as seen with KSHV inhibition of STAT6 phosphorylation and H. pylori inhibition of Sox2 expression. These layers ensure tight control of IL-4 responses.
regulation of interleukin-4-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT6 | Lymphoma, immune dysregulation | STAT6 knockout or point-mutant cell lines |
| Bcl-xL | Chemoresistance in cancer | Bcl-xL overexpression in B-cell lines |
| Sox2 | Gastric intestinal metaplasia | H. pylori-infected gastric organoids |
| KSHV ORF | Kaposi's sarcoma, viral latency | KSHV-infected endothelial cells |
| PP2A | Cancer, autoimmune disorders | PP2A knockout or knockdown models |
Cancer and Chemoresistance
IL-4-mediated signaling regulates apoptosis and chemoresistance. Stat6-dependent upregulation of Bcl-xL protects B cells from apoptosis, and epigenetic determinants involving Bcl-X(L) and Bax influence resistance to etoposide in tumor microenvironments. Dysregulation of this pathway can promote tumor survival.
Gastric Metaplasia and Infection
Helicobacter pylori induces gastric mucosal intestinal metaplasia by inhibiting IL-4-mediated HMG box protein Sox2 expression. This highlights how pathogens can subvert IL-4 signaling to drive preneoplastic changes.
Viral Latency and Apoptosis
Kaposi's sarcoma-associated herpesvirus inhibits IL-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency. This demonstrates a viral strategy to evade immune clearance by modulating IL-4 signaling.
From regulation of interleukin-4-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does STAT6 phosphorylation drive IL-4-mediated proliferation? | STAT6 knockout cell line |
| What is the effect of dominant-negative STAT6 on signaling? | STAT6 point-mutation knock-in |
| How does PP2A regulate STAT6 dephosphorylation? | PP2A overexpression or knockout |
| Does SHIP positively regulate IL-4-mediated proliferation? | SHIP knockout or overexpression |
| Can Bcl-xL rescue B cells from apoptosis? | Bcl-xL overexpression in primary B cells |
| How does KSHV inhibit STAT6 phosphorylation? | KSHV ORF overexpression in reporter cells |
How to Study the regulation of interleukin-4-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Identify regulators of IL-4 signaling |
| Phosphoproteomics | Phosphorylation changes | Quantify STAT6 activation |
| RNA-seq | Transcriptional changes | Discover downstream targets |
| Apoptosis assay | Cell survival | Assess Bcl-xL protection |
| Western blot | Protein expression and phosphorylation | Validate STAT6 and PP2A activity |
| Co-immunoprecipitation | Protein-protein interactions | Study STAT6 complexes |
| Luciferase reporter | Transcriptional activity | Measure STAT6-driven promoters |
CRISPR-Cas9 Knockout Screening
CRISPR knockout screens can identify genes that regulate IL-4-mediated signaling, such as STAT6, PP2A, and SHIP [1, 2, 3]. Pooled sgRNA libraries enable unbiased discovery of positive and negative regulators.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics quantifies changes in STAT6 phosphorylation upon IL-4 stimulation, revealing regulatory dynamics [1, 3].
Transcriptional Profiling
RNA-seq after IL-4 treatment identifies downstream target genes such as Bcl-xL and Sox2, providing functional readouts of pathway regulation [4, 6].
Apoptosis Assays
Flow cytometry-based apoptosis assays measure the protective effects of IL-4-mediated Bcl-xL upregulation in B cells [4, 8].
How CRISPR Can Be Used to Study GO:1902214 regulation of interleukin-4-mediated signaling pathway
Knockout
CRISPR knockout of STAT6, PP2A, or SHIP can reveal their essential roles in regulating IL-4-mediated signaling [1, 2, 3]. Knockout cell lines provide clean backgrounds for mechanistic studies.
Point Mutation
Introducing point mutations in STAT6, such as those found in dominant-negative variants, allows precise interrogation of phosphorylation sites and regulatory domains.
Knock-in
Knock-in of tagged STAT6 or PP2A enables live-cell imaging and proteomic analysis of signaling dynamics.
Overexpression
Overexpression of Bcl-xL or SHIP can enhance IL-4-mediated survival and proliferation, providing gain-of-function models [2, 4].
How EDITGENE Supports regulation of interleukin-4-mediated signaling pathway Research
Researchers studying regulation of interleukin-4-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating IL-4 responses. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of interleukin-4-mediated signaling pathway research.
Frequently Asked Questions About regulation of interleukin-4-mediated signaling pathway
What is GO:1902214?
GO:1902214 is the Gene Ontology term for regulation of interleukin-4-mediated signaling pathway, describing any process that modulates the frequency, rate or extent of IL-4 signaling [1, 5].
What genes are involved in regulation of interleukin-4-mediated signaling pathway?
Key genes include STAT6, PP2A, SHIP, Bcl-xL, and SOCS proteins [1, 2, 3, 4, 5].
How is IL-4 signaling regulated?
IL-4 signaling is regulated by phosphorylation and dephosphorylation of STAT6, dominant-negative variants, and positive regulators like SHIP [1, 2, 3].
What diseases are associated with dysregulation of IL-4 signaling?
Dysregulation is linked to cancer, gastric metaplasia, viral latency, and immune disorders [6, 7, 8].
What is the role of STAT6 in IL-4 signaling?
STAT6 is the primary transcription factor that mediates IL-4 responses, and its phosphorylation is essential for signal transduction [1, 5].
How does PP2A regulate IL-4 signaling?
PP2A dephosphorylates STAT6, thereby attenuating IL-4-mediated signaling.
Can CRISPR be used to study IL-4 signaling regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of regulatory mechanisms [1, 2, 3, 4].
What methods are used to study regulation of IL-4 signaling?
Common methods include phosphoproteomics, RNA-seq, apoptosis assays, and CRISPR screens [1, 2, 3, 4, 6, 8].
What is the role of SHIP in IL-4 signaling?
SHIP positively regulates IL-4-mediated proliferation.
How does KSHV modulate IL-4 signaling?
KSHV inhibits IL-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.
Conclusion
GO:1902214, regulation of interleukin-4-mediated signaling pathway, is a critical biological process that ensures balanced immune responses. Its dysregulation contributes to cancer, infection, and immune disorders, making it a rich area for research. By leveraging CRISPR-based models and advanced omics, researchers can uncover novel regulatory mechanisms and therapeutic targets [1, 2, 3, 4, 5, 6, 7, 8].
References
- 1. Patel BK et al.. 1998. Regulation of interleukin 4-mediated signaling by naturally occurring dominant negative and attenuated forms of human Stat6.. Proc Natl Acad Sci U S A 95(1):172-7 PMID: 9419348
- 2. Giallourakis C et al.. 2000. Positive regulation of interleukin-4-mediated proliferation by the SH2-containing inositol-5'-phosphatase.. J Biol Chem 275(38):29275-82 PMID: 10875931
- 3. Woetmann A et al.. 2003. Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling.. J Biol Chem 278(5):2787-91 PMID: 12426308
- 4. Wurster AL et al.. 2002. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL.. J Biol Chem 277(30):27169-75 PMID: 12023955
- 5. Takeda K et al.. 1997. STAT6: its role in interleukin 4-mediated biological functions.. J Mol Med (Berl) 75(5):317-26 PMID: 9181473
- 6. Asonuma S et al.. 2009. Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression.. Am J Physiol Gastrointest Liver Physiol 297(2):G312-22 PMID: 19520737
- 7. Cai Q et al.. 2010. Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.. J Virol 84(21):11134-44 PMID: 20719954
- 8. Taylor ST et al.. 2000. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.. J Natl Cancer Inst 92(1):18-23 PMID: 10620629
